Five-Cent Diabetes Pill From 1958 May Be New Cancer Drug
The next new treatment for breast, colon and prostate cancers, among others, may be a diabetes drug first approved in 1958.
-
-
Recent Posts
-
-
Drugs
Use diabetes drug with caution, says ministry
Avandia had been registered since July 2000, had closely monitored the drug following information on excess water retention and risk of heart failure and adverse cardiovascular effects connected to its consumption.
New York Man Alleges that Diabetes Medication Actos Caused Bladder Cancer
Actos is a type 2 diabetes medication that has been linked to bladder cancer in a number of studies. According to a recent report in Consumer Reports, the risks of taking Actos outweigh the benefits for most patients.
Research: More patients may benefit from effective antidiabetic drug
The antidiabetic drug metformin is not prescribed for patients with reduced kidney function because the risk of adverse effects has been regarded as unacceptably high.
Coenzyme Q10 may protect against heart disease in type 2 diabetes patients
Taking Coenzyme Q10 supplements may help prevent heart disease in patients with type 2 diabetes mellitus, according to a study most recently published in Diabetologia. The study was conducted in an animal model.
Many Diabetic Patients May Benefit From Cardioprotective Medications
Some patients with type 2 diabetes experience kidney problems that cause them to excrete increased amounts of the protein albumin in their urine. These patients have a considerably higher risk of developing heart problems.
Experimental combo treatment worsens type 1 diabetes
A treatment regimen that is effective in preventing diabetes in a mouse model of the disease leads to worsening disease in patients with type 1 diabetes, according to a study published online June 20 in Diabetes.
Preliminary Results in Aliskiren Trial Show Drug ‘May Even Be Harmful’
Preliminary results from the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) do not support administration of aliskiren on top of standard therapy with renin-angiotensin-aldosterone system (RAAS) blockade.
Ethical Dilemmas Contribute To ‘Critical Weaknesses’ In FDA Postmarket Oversight
Ethical challenges are central to persistent “critical weaknesses” in the national system for ensuring drug safety, according to a commentary by former Institute of Medicine members published in the New England Journal of Medicine.
Pancreatitis Risk May Be Lowered By Statin Therapy
According to results of an analysis published in JAMA, stain therapy is connected with a lower risk of pancreatitis in patients with normal or mildly elevated triglyceride levels.
TYPE II’s: FDA Approves Generic Versions of Actos
The first generic versions of pioglitazone (Actos) have been approved by the U.S. Food and Drug Administration to help adults with type 2 diabetes control blood glucose levels.
FDA Okays Tradjenta As Add-On Therapy To Insulin
Eli Lilly and Co. (LLY:Quote) said Friday that the U.S. Food and Drug Administration has approved a supplemental new drug application, or sNDA, for Tradjenta tablets for use as add-on therapy to insulin.
FDA Approves Lucentis for Diabetic Eye Disorder
The U.S. Food and Drug Administration on Friday recommended wider approval of Roche Holding eye drug, Lucentis. An estimated 75,000 new cases of diabetic macular edema develop each year in the U.S.
TB Vaccine Might Reverse Type 1 Diabetes
A vaccine used for decades to treat tuberculosis might not only reduce the need for daily insulin shots but actually reverse the disease itself, reports Bloomberg.
Biological Clock Chemical Offers Diabetes Treatment Hope
A paper published July 13 in an advance online issue of Science reveals that biologists from California’s San Diego University have discovered a chemical, called KL001, which provides a unique and novel target for the development of drugs.
AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus (Type 2) to be Presented
The 12-week study, investigated AMR101 as a treatment for patients with high triglycerides (greater than or equal to 200 and <500 mg/dL) who were also on statin therapy for elevated low-density lipoprotein cholesterol. Of 702 total patients, 514 (73%) had diabetes mellitus-2.
Diabetes drug linked to increased risk of bladder cancer
The results show that more than two years daily exposure to pioglitazone doubles the risk of bladder cancer. However, the authors stress that, in absolute terms, the risks are low – up to 137 extra cases per 100,000 person years.
Jentadueto® (linagliptin/metformin hydrochloride) recommended for approval in Europe
The EMA’s Committee for Medicinal Products for Human Use or CHMP recommended the approval of Jentadueto for use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes who are inadequately controlled.
Positive Results in Linagliptin Trial
In the U.S., African Americans and other ethnic minorities are significantly underrepresented in clinical trials. This is the first published trial of a DPP-4 inhibitor specifically conducted in black or African American adult patients with type 2 diabetes.
New Research Suggests Novel Insulin Sensitizer Works
A study published online in the Journal of Biological Chemistry showed a new drug to treat diabetes being developed by Metabolic Solutions Development Company, LLC (MSDC), MSDC-0602, improved insulin resistance and inflammation in obese mice.